Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanita, Rome, Italy.
Euro Surveill. 2014 Oct 23;19(42):20939. doi: 10.2807/1560-7917.es2014.19.42.20939.
Consecutive non-replicate clinical isolates (n=191) of carbapenem non-susceptible Enterobacteriaceae were collected from 21 hospital laboratories across Italy from November 2013 to April 2014 as part of the European Survey on Carbapenemase-producing Enterobacteriaceae (EuSCAPE) project. Klebsiella pneumonia carbapenemase-producing K. pneumoniae (KPC-KP) represented 178 (93%) isolates with 76 (43%) respectively resistant to colistin, a key drug for treating carbapenamase-producing Enterobacteriaceae. KPC-KP colistin-resistant isolates were detected in all participating laboratories. This underscores a concerning evolution of colistin resistance in a setting of high KPC-KP endemicity.
连续收集了 2013 年 11 月至 2014 年 4 月间意大利 21 家医院实验室的 191 株耐碳青霉烯类非复制性临床分离株(肠杆菌科),这是欧洲产碳青霉烯酶肠杆菌科(EuSCAPE)项目的一部分。肺炎克雷伯菌碳青霉烯酶(KPC-KP)占 178 株(93%),分别有 76 株(43%)对多黏菌素耐药,多黏菌素是治疗产碳青霉烯酶肠杆菌科的关键药物。所有参与实验室均检测到 KPC-KP 多黏菌素耐药株。这突显了在高 KPC-KP 流行地区,多黏菌素耐药性令人担忧的演变。